Median Technologies Is Releasing Full Year 2020 Financial Results (audited) as Well as Q1 2021 Business Activity Indicators, Showing a Very Strong Growth - Seite 3

In the first quarter of 2021, the Group also announced the signing of a major research collaboration with the University of California San Diego. The purpose of this collaboration is to conduct a new validation study for the iBiopsy clinical development plan in Non-Alcoholic Steatohepatitis (NASH), which will be conducted on an independent cohort of over 300 patients. The first results of this study are expected in the first quarter of 2022.

In addition, the company announced the initiation of a new clinical development plan for the early diagnosis of lung cancer, with first results on a cohort of 1,800 patients to be published in the second half of 2021.

"2020 was an excellent year in terms of our iCRO business performance, stock performance and progress in our iBiopsy clinical development and partnership plans. The recent funding round gives us the means to pursue our ambitions to simultaneously advance our indications for early diagnosis of liver cancer, NASH and, as recently announced, lung cancer as well," said Fredrik Brag, CEO and founder of Median Technologies. "2021 is shaping up to be a very exciting year, with revenue from our iCRO business already up by 86% in the first quarter compared to Q1 revenue last year. Our order backlog has increased despite the very significant increase in invoicing. This year will also see the continued publication of technology and clinical validation results for iBiopsy, as well as the continued implementation of our policy on setting up partnerships as a basis for future development".

Median informs its shareholders and the financial community that its annual financial report on the accounts for the year ended December 31, 2020 was made public and filed with the AMF.

The annual financial report is available on the company website: www.mediantechnologies.com/investors/

Forward-Looking Statements: This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Median’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities such as the absence of guarantee that the service if approved will be commercially successful, the future approval, Median’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the AMF made by Median, other than as required by applicable law, Median does not undertake any obligation to update or revise any forward-looking information or statements.